Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).

Oncotarget · 2016 · PMC5342029 · PMID 27659533

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

tended towards significancep=0.06so close (0.05 < p ≤ 0.1)

However, the association between VEGF values and PFS tended towards significance (p=0.06 at D1 and p=0.08 at D7).

also in 152 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.